FDA and National Cancer Institute unveil "inter-agency agreement" to accelerate cancer drug development in conjunction with American Society of Clinical Oncology meeting. Task force to increase collaboration between the two agencies will be co-chaired by FDA Assistant Commissioner for Planning Theresa Mullin, PhD, and NCI Deputy Director for Strategic Scientific Initiatives Anna Barker, PhD. FDA cited the collaboration with NCI with aiding approval of Millennium's multiple myeloma treatmentVelcade (1"The Pink Sheet" May 19, 2003, p. 3)...
You may also be interested in...
HHS Secretary Thompson vows to make "vast improvements" in expediting oncology drug development using the FDA/National Cancer Institute Interagency Oncology Task Force
Creating a mechanism for electronic IND applications will be the first project undertaken by a collaboration between FDA and the National Cancer Institute
The USP’s general chapter on nitrosamine impurities provides guidance on assessing risks and testing levels of the carcinogens in pharmaceuticals.